Sustained and cancer cell targeted cytosolic delivery of Onconase results in potent antitumor effects

Journal of Controlled Release

Volumn 159, Issue 3, 2012, Pages 346-352

  Zhao, Hong Liang ^a   Xue, Chong ^a   Du, Ji Liang ^a   Ren, Min ^a   Xia, Shan ^a   Cheng, Yuan Guo ^b   Liu, Zhi Min ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Drug delivery system; Fusion protein; Onconase

Indexed keywords

ANTI-TUMOR AGENTS; ANTI-TUMOR EFFICACY; ANTIBODY FRAGMENT; ANTICANCER TREATMENT; ANTITUMOR EFFECT; BREAK DOWN; BROKEN DOWN; CANCER CELLS; CLINICAL UTILITY; CYTOSOLIC; DRUG DELIVERY SYSTEM; EPITHELIAL CELL ADHESION; FUSION PROTEINS; HUMAN SERUM ALBUMINS; HUMAN TUMORS; IN-VIVO; LONG JOURNEY; MECHANISM OF ACTION; MULTI-STAGE; ONCONASE; SUB-CELLULAR; TUMOR ACCUMULATION;

CELL ADHESION; DRUG DELIVERY; ENZYME INHIBITION; TUMORS;

CELLS;

ANTIBODY; CYTOSOL RECEPTOR; DISULFIDE; DRUG CARRIER; EPITHELIAL CELL ADHESION MOLECULE; HUMAN SERUM ALBUMIN; MEMBRANE PROTEIN; RANPIRNASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER STAGING; CELL DIVISION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG HALF LIFE; DRUG SCREENING; DRUG UPTAKE; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; KIDNEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYTOSOL; DRUG DELIVERY SYSTEMS; FEMALE; HT29 CELLS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LIVER FUNCTION TESTS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; PICHIA; RECOMBINANT FUSION PROTEINS; RIBONUCLEASES; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862825933     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.019     Document Type: Article

References (31)

1. W. Ardelt, S.M. Mikulski, and K. Shogen Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases J. Biol. Chem. 266 1991 245 251
2. W. Ardelt, K. Shogen, and Z. Darzynkiewicz Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes Curr. Pharm. Biotechnol. 9 2008 215 225
3. X. Dhalluin, and A. Scherpereel Chemotherapy and radiotherapy for mesothelioma Recent Results Cancer Res. 189 2011 127 147
4. V.M. Vasandani, Y.N. Wu, S.M. Mikulski, R.J. Youle, and C. Sung Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily Cancer Res. 56 1996 4180 4186
5. H.L. Zhao, C. Xue, Y. Wang, X.Q. Yao, and Z.M. Liu Increasing the cell viability and heterologous protein expression of Pichia pastoris mutant deficient in PMR1 gene by culture condition optimization Appl. Microbiol. Biotechnol. 81 2008 235 241
6. H.L. Zhao, Q. He, C. Xue, B. Sun, X.Q. Yao, and Z.M. Liu Secretory expression of glycosylated and aglycosylated mutein of Onconase from Pichia pastoris using different secretion signals and their purification and characterization FEMS Yeast Res. 9 2009 591 599
7. Z. Yao, W. Dai, J. Perry, M.W. Brechbiel, and C. Sung Effect of albumin fusion on the biodistribution of interleukin-2 Cancer Immunol. Immunother. 53 2004 404 410
8. T.Y. Chao, L.D. Lavis, and R.T. Raines Cellular uptake of ribonuclease A relies on anionic glycans Biochemistry 49 2010 10666 10673
9. J. Matousek, J. Soucek, T. Slavík, M. Tománek, J.E. Lee, and R.T. Raines Comprehensive comparison of the cytotoxic activities of Onconase and bovine seminal ribonuclease Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 2003 343 356
10. Y.A. Goo, and D.R. Goodlett Advances in proteomic prostate cancer biomarker discovery J. Proteomics 73 2010 1839 1850
11. B.T. van der Gun, L.J. Melchers, M.H. Ruiters, L.F. de Leij, P.M. McLaughlin, and M.G. Rots EpCAM in carcinogenesis: the good, the bad or the ugly Carcinogenesis 31 2010 1913 1921
12. M. Trzpis, P.M. McLaughlin, L.M. de Leij, and M.C. Harmsen Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule Am. J. Pathol. 171 2007 386 395
13. M. Rodríguez, G. Torrent, M. Bosch, F. Rayne, J.F. Dubremetz, and M. Ribó Intracellular pathway of Onconase that enables its delivery to the cytosol J. Cell Sci. 120 2007 1405 1411
14. H.A. Erickson, M.D. Jund, and C.A. Pennell Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition Protein Eng. Des. Sel. 19 2006 37 45
15. I. Ojima Guided molecular missiles for tumor-targeting chemotherapy - case studies using the second-generation taxoids as warheads Acc. Chem. Res. 41 2008 108 119
16. X. Chen, Y. Bai, J.L. Zaro, and W.C. Shen Design of an in vivo cleavable disulfide linker in recombinant fusion proteins Biotechniques 49 2010 513 518
17. G. Saito, J.A. Swanson, and K.D. Lee Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Deliv. Rev. 55 2003 199 215
18. S.M. Mikulski, W. Ardelt, K. Shogen, E.H. Bernstein, and H. Menduke Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos J. Natl. Cancer Inst. 82 1990 151 153
19. D.L. Newton, H.J. Hansen, S.M. Mikulski, D.M. Goldenberg, and S.M. Rybak Potent and specific antitumor effects of an anti-CD22 targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma Blood 97 2001 528 535
20. C.H. Chang, P. Sapra, S.S. Vanama, H.J. Hansen, I.D. Horak, and D.M. Goldenberg Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin Blood 106 2005 4308 4314
21. C.H. Chang, P. Gupta, R. Michel, M. Loo, Y. Wang, and T.M. Cardillo Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells Mol. Cancer Ther. 9 2010 2276 2286
22. C. Di Paolo, J. Willuda, S. Kubetzko, I. Lauffer, D. Tschudi, and R. Waibel A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity Clin. Cancer Res. 9 2003 2837 2848
23. N.K. Sundlass, and R.T. Raines Arginine residues are more effective than lysine residues in eliciting the cellular uptake of Onconase Biochemistry 50 2011 10293 10299
24. Y. Sakurai, H. Hatakeyama, Y. Sato, H. Akita, K. Takayama, S. Kobayashi, S. Futaki, and H. Harashima Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA Biomaterials 32 2011 5733 5742
25. C. Bachran, A. Weng, D. Bachran, S.B. Riese, N. Schellmann, M.F. Melzig, and H. Fuchs The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice Br. J. Pharmacol. 159 2010 345 352
26. E.M. Stier, M. Mandal, and K.D. Lee Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells Mol. Pharm. 2 2005 74 82
27. A.G. Polson, J. Calemine-Fenaux, P. Chan, W. Chang, E. Christensen, and S. Clark Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection Cancer Res. 69 2009 2358 2364
28. H. Fuchs, C. Bachran, T. Li, I. Heisler, H. Dürkop, and M. Sutherland A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice J. Control. Release 117 2007 342 350
29. D.L. Kukis, I. Novak-Hofer, and S.J. DeNardo Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer Cancer Biother. Radiopharm. 16 2001 457 467
30. J.W. Yoo, D.J. Irvine, D.E. Discher, and S. Mitragotri Bio-inspired, bioengineered and biomimetic drug delivery carriers Nat. Rev. Drug Discov. 10 2011 521 535
31. H. Lorberboum Galski Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases Expert Opin. Drug Deliv. 8 2011 605 621